TFFP News and Press, TFF Pharmaceuticals Inc - Ordinary Shares From 05/13/21

Pivotal Trials to Begin in 2H-2021 for Voriconazole Inhalation Powder for the Treatment of Invasive Pulmonary Aspergillosis (IPA) and Tacrolimus Inhalation Powder for Immunosuppression in Solid Organ Transplantation Patent Filed for Once-a-Day Dosing for Tacrolimus Inhalation ...

Company conference call and webcast at 4:30 PM EDT TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, toda...

Company’s Thin Film Freezing platform to be developed for use in rapidly neutralizing chemical and biological threats at vulnerable tissue barriers to increase soldier protection and decrease operational burden TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stag...

TFF Pharmaceuticals (TFFP) announces that it has priced an underwritten offering of 2.86M shares at an offering price of $14/share.Shares down more than 7% premarket.Intends to use the net proceeds for working capital and general corporate purposes.The offering consists of 2.14M sha...

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (“TFF”) technology platform, today announced that it has priced an underwritten ...

The company's generic technology provides important benefits and is applicable in a wide range of situations. The company has two dozen shots at goal and is still adding. Cash isn't a problem for at least a year and revenues are likely to kick in well before that. None of their TF...

Image source: The Motley Fool. TFF Pharmaceuticals Inc. (NASDAQ: TFFP) Q4 2020 Earnings Call Mar 10, 2021 , 4:30 p.m. ET Continue reading For further details see: TFF Pharmaceuticals Inc. Common Stock (TFFP) Q4 2020 Earnings Call Transcript ...

TFF Pharmaceuticals, Inc. (TFFP) Q4 2020 Earnings Conference Call March 10, 2021 04:30 PM ET Company Participants Paul Sagan - Investor Relations Glenn Mattes - President & Chief Executive Officer Dale Christensen - Director, Clinical Development Kirk Coleman - Chief Financial Officer Bil...

TFF Pharmaceuticals (TFFP): Q4 GAAP EPS of -$0.26 misses by $0.04.Cash and cash equivalents of $35.3MPress Release For further details see: TFF Pharmaceuticals EPS misses by $0.04

Reports positive Phase 1 study results for Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder Awarded subcontract license by U.S. government agency to formulate biologic countermeasures to be used by the U.S. military Announces feasibility agreements with ...